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Objective: To describe medroxyprogesterone acetate (MPA) levels among Kenyan depot medroxyprogesterone acetate (DMPA) users in the
FEM-PrEP HIV prevention trial, and to compare MPA levels between ARV for HIV prevention (treatment) and placebo groups.
Study Design:We measured MPA in previously collected plasma samples from 63 Kenyan trial participants who used DMPA for one or two
complete intervals. We separately assessed MPA levels among the nine DMPA users who became pregnant at this site.
Results: Mean MPA levels at the end of each 12 week injection interval were 0.37 ng/ml (95% CI: 0.25, 1.99) and 0.28 ng/ml (95% CI:
0.19, 1.22) among participants assigned TDF/FTC and 0.49 (95% CI: 0.40, 1.27) and 0.39 (95% CI: 0.31, 1.17) among those assigned
placebo. The difference between groups was not statistically significant overall, or in an analysis which adjusted for the observed low
adherence to TDF/FTC. Unanticipated findings of this analysis were low 12-week MPA levels among DMPA users in both study arms. Of 61
women who contributed data for the first DMPA injection interval, 26.2% had MPA levelsb0.1 ng/ml and 9.8% had levels below the
detection level (0.02 ng/ml) at 12 weeks post-injection. Levels were similar at the end of the second injection interval. Five of nine women
who became pregnant had levels below 0.15 ng/mL at the time of their last negative pregnancy test.
Conclusions: Use of TDF/FTC did not appear to affect serum MPA levels, however we found lower than expected MPA concentrations at
the end of the dosing interval among DMPA users in the FEM-PrEP trial, the cause of which are unknown.
Implications: This study presents some of the few available data on MPA levels among DMPA users in Africa. The low levels among users
described here, together with a number of pregnancies among DMPA users, are potentially concerning and require further investigation.
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Around the world an estimated 48 million women rely on
injectable contraceptives for pregnancy prevention [1,2]. This
figure has increased substantially over the last two decades,
especially in lesser developed regionswhere injectablemethods
are increasingly available and popular [3,4]. In Sub-Saharan
Africa, nearly half of all modern contraceptive users are using
injectable contraceptives [1]. As in the rest of the world, most
injectable users in Africa use the three-month progestin-only
injectable depot-medroxyprogesterone acetate (DMPA) [4].
Despite the increasing popularity of DMPA, few studies
report on pregnancy rates or medroxyprogesterone acetate
(MPA) levels among diverse populations in low resource
settings. Recently, we noted several unexpected pregnancies
amongDMPAusers in theBondo,Kenya site of the FEM-PrEP
Trial for HIV Prevention among African Women. These
pregnancies, along with higher overall pregnancy rates among
women randomized to tenofovir/emtricitabine (TDF/FTC) [5],
raised concerns that use of the study drug could be interfering
with the effectiveness of hormonal contraceptives. Even though
TDF/FTC is not known to be a hepatic enzyme inducer, and
would not be expected to affect contraceptive efficacy, wewere
concerned about potential interactions other than hepatic
enzyme induction. In response to this concern, we evaluated
MPA levels in a sub-sample of DMPA users, and compared
MPA levels by study arm. We also evaluated MPA levels in
women who conceived while using DMPA.2. Materials and methods
This is a secondary analysis of data from FEM-PrEP, a
randomized placebo-controlled trial of daily oral TDF/FTC
to prevent HIV acquisition, that enrolled 2120 HIV-negative
women aged 18–35 at four sites in South Africa, Kenya and
Tanzania. Participants were asked to use study drug (TDF/
FTC or placebo) daily for 52 weeks and attend study visits
every four weeks. Use of an effective, non-barrier method of
contraception, including sterilization, IUD, progestin im-
plants, injectables (DMPA or NET-En), or combined oral
contraceptives (COCs) was required at the time of
enrollment and encouraged, but not required, at follow-up.
The FHI 360 Protection of Human Subjects Committee
(PHSC) and institutional review boards at the study sites
approved the study protocol, and participants consented to
additional investigation of collected blood samples. The trial
was stopped early because of lack of effect of TDF/FTC on
HIV acquisition, subsequently found to be due to poor
adherence. Effectiveness and safety data from FEM-PrEP
and other study details have been published previously [5].
For this secondary analysis, we evaluated MPA levels in
women from the Bondo, Kenya site who: 1) had a DMPA
injection at enrollment and 2) completed their week 4, 8 and
12 study visits on schedule. A total of 63 women met these
criteria: 11 new DMPA users and 52 continuing users. Ofthese 63, 49 further completed a second interval of DMPA
use and made their week 16, 20 and 24 study visits (Fig. 1).
Because of incomplete DMPA injection data from other
FEM-PrEP countries, we were only able to evaluate samples
from the Kenya site, where injections were given on site by
study nurses, We used theses specimens to compare MPA
levels between women randomized to TDF/FTC and those
randomized to placebo. Sample size was based on the totality
of women eligible for the analysis, and not formal
power considerations. Nonetheless, our observed sample
size (36 and 26, respectively, in the placebo and TDF/FTC
groups) provided approximately 76% power to detect a
50% reduction in trough (week 12) MPA concentrations
(two-sided alpha=0.05) among TDF/FTC users, assuming a
coefficient of variation of 0.9 (the average observed value),
with still greater power for repeated measures (interval)
analysis. We separately assessed MPA levels for nine of 12
DMPA users at the Bondo site who tested positive for
pregnancy during the study.
Sites recorded demographic and basic physical examina-
tion information including height and weight on standard-
ized case report forms at enrollment. At enrollment and each
follow-up visit, participants provided blood samples, had
urine tested for pregnancy, and reported current contracep-
tive and concomitant medication use during the previous
4-week interval. In the Bondo site, women using DMPA
received intramuscular injections at the study clinic during
follow-up visits; injections were administered after blood
was drawn. The DMPA used at the site was Depo-Progestin
manufactured by PT Harsen in Indonesia, distributed by PSI
and labeled as Femiplan in Kenya.
Plasma samples used for this analysis were drawn
between July 2009 and March 2011. Samples were prepared
and kept frozen at -20 °C for up to 33 months prior to
shipment to PPD Development Labs (Richmond, VA, USA)
where MPA levels were determined via a validated sensitive
and selective high-performance liquid chromatography
method coupled with tandem mass spectrometry
(HPLC-MS/MS). The detection limit for MPA was
0.02 ng/mL and was determined during validation of the
assay according to the vendor's standard operating procedure
requirements. Back-calculated calibration standards, and
intra-assay quality controls met acceptable precision and
accuracy criteria (+/− 20%). In addition, prior to analysis of
clinical samples, acceptable precision and accuracy runs
were conducted in order to support continued use of the
bioanalytical method. All correlation coefficients
wereN0.997. Assay precision, expressed as the percent
coefficient of variation (%CV), averaged 5.88%, 5.54%,
7.96%, 5.17% and 3.33% for the 0.05, 0.1, 0.3, 1.0, and
3.75 ng/mL quality control (QC) standards, respectively.
Assay accuracy was expressed as the ratio (%) between
the mean of the QC standard and the theoretical concentra-
tion of that standard resulting in inter-assay accuracy
of 102.9–108.3%, with intra-assay accuracy between
98.8–115.5%.
Recruited into Sub-study: 63










Total: 65  
Fig. 1. Study population and intervals contributed to analyses.
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(TFV) in plasma and tenofovir-diphosphate (TFV-DP) in
upper-layer packed cells (ULPC) concentrations at four-
week intervals had previously been measured [6]. For the
current analysis, we defined “good” adherence as having
both plasma TFV exceeding 10 ng/ml and ULPC TFV-DP
exceeding 100,000 femtomoles, consistent with taking four
or more doses of TDF/FTC per week [7].
We summarized MPA levels by study arm for up to two
12-week intervals. We evaluated the effects of TDF/FTC use
(good adherence, non-zero adherence, or no adherence/
placebo), baseline BMI (b=20 orN20), age (18–24, 25–29,
or 30+) and previous MPA use (i.e., either presence of MPA
in the plasma sample taken at the time of enrollment or
second interval of use in sub-study) on MPA levels. For each
participant contributing a complete set of data (i.e., injection
visit and weeks 4, 8, and 12 post-injection), we used a linear
trapezoidal procedure to compute a crude area under the
curve (AUC) from the injection visit through the end of the
12-week dosing interval (we considered this a crude AUC
measure due to sparse sampling at 4-week intervals, which
also precluded making reasonable estimates of other PK
parameters such as maximum concentration and time to
maximum concentration). We estimated the crude AUC
separately for women in interval 1 with no previous DMPA
use, interval 1 with previous DMPA use, and interval 2. The
effect of cumulative TDF/FTCuse during the injection interval
(number of 4-week periods with good adherence), MPA use in
the previous interval, BMI, and age were then applied to
log-transformedAUCs using amixed effects linearmodel with
random intercept term. We also calculated the proportion of
women with values below the presumed contraceptive
threshold for DMPA (0.1 ng/ml) [8,9].3. Results
We excluded interval 1 or interval 2 data from two
women indicating either no injection had occurred (despite a
data form entry to the contrary) or results strongly indicating
that the injection was given before drawing of the 12-week
blood sample, leaving 61 women contributing data to the
first interval of DMPA use, 49 women contributing to a
second interval of use, 62 women contributing to at least one
interval, and a total of 110 intervals of use (65 Placebo, 45
TDF/FTC; Fig. 1).
In this sub-analysis, women in the placebo group were
less likely to be married than women in the TDF/FTC group
(72% versus 96%), but the two groups were otherwise
similar in their demographic and physical characteristics at
enrollment, including BMI (Table 1). Fifty two women
(84%) reported using DMPA as their contraceptive method
at screening, but only 42 (81%) had detectable MPA at
enrollment. Prior dates of injections could not be consistently
obtained, so we do not know how long the women with no
evidence of MPA at enrollment had gone between injections.
Mean MPA levels in the initial interval of use were 2.13,
0.95, and 0.44 ng/mL at weeks 4, 8, and 12, respectively.
The 12-week troughs were about 0.1 ng/mL lower in the
TDF/FTC group, but the differences were not statistically
significant (p= .07 for first interval, p= .34 for second
interval, and p= .09 when accounting for repeated interval
data) (Fig. 2).
Of 61 women with data following their first in-study
DMPA injection, 16 (26.2%) had MPA levelsb0.1 ng/ml at
their week 12 visit and 6 (9.8%) had undetectable MPA
levels (Table 2). Similar results were apparent following
their second in-study DMPA injection, with 13 of 49 women
Table 1










18–24 36.1% 7.7% 24.2%
25–29 22.2% 38.5% 29.0%
30–35 41.7% 53.8% 46.8%
Median (Range) 28 (19–35) 30 (22–34) 29 (19–35)
Height (cm)
Mean (SD) 167.6 (6.9) 165.0 (6.0) 166.5 (6.6)
Median (Range) 167 (146–180) 165 (152–177) 166 (146–180)
Weight (kg)
Mean (SD) 60.6 (9.2) 58.5 (6.7) 59.7 (8.3)
Median (Range) 59 (39–81) 59 (41–71) 59 (39–81)
BMI
Mean (SD) 21.6 (3.0) 21.5 (2.6) 21.5 (2.8)
Median (Range) 21 (17–29) 22 (16–29) 21 (16–29)
Years of school completed
b= 9 80.6% 88.5% 83.9%
N 9 19.4% 11.5% 16.1%
Median (Range) 8 (0–12) 8 (0–12) 8 (0–12)
Marital Status
Notmarried, not livingwithman 27.8% 3.8% 17.7%
Married, not living with man 2.8% 3.8% 3.2%
Married, living with man 69.4% 92.3% 79.0%
Ever been pregnant
Yes 100% 100% 10%
Number of pregnancies
Median (Range) 3 (1–7) 4 (1–6) 3 (1–7)
Contraceptive used at screening
Oral contraceptives 8.3% 3.8% 6.5%
Injectable 80.6% 88.5% 83.9%
None 11.1% 7.7% 9.7%
43K. Nanda et al. / Contraception 94 (2016) 40–47(26.5%) having MPA levels below 0.1 ng/ml twelve weeks
after injection and 4 (8.2%) with undetectable levels.
BMI, previous use of DMPA, and use of TDF/FTC did
not significantly affect log-transformed MPA values atWhiskers drawn to the 5th and 95th percentiles
Fig. 2. MPA levels over time since enrollment by treatment groweeks 4, 8, and 12 (results not shown). Although crude AUC
values for MPA were higher in the placebo group than in the
active group (Table 3), there was no significant effect of
TDF/FTC use on log-transformed AUC values in a model
that adjusted for actual TDF/FTC use (Table 4). In
exploratory analysis, the geometric mean AUC ratio for
injection intervals with at least one 4-week period with
good-to-excellent TDF/FTC adherence versus intervals
without any evidence of good TDF/FTC use (including
women assigned placebo) was 0.91 (95% CI: 0.78–1.08)
after adjusting for repeated measures on subjects. However,
there were too few intervals with good-to-excellent
adherence throughout the entire injection interval to explore
this further.
Twelve women (seven assigned to TDF/FTC and five
assigned to placebo) tested positive for pregnancy while on
DMPA. Of the nine with specimens available for analysis,
five had MPA levelsb0.15 ng/mL at the time of their last
negative pregnancy test and four of those had levels below
the detection limit (Fig. 3).4. Discussion
In our sub-analysis of MPA levels among DMPA users in
the Bondo, Kenya site of the FEM-PrEP study we found
similar MPA levels across two DMPA dosing intervals
among women assigned to TDF/FTC and placebo, adjusting
for study drug adherence. While our results suggest that
concomitant oral TDF/FTC use does not dramatically affect
MPA levels among users of DMPA, we did not have high
power to detect smaller than 50% reductions in trough
concentrations. Also, we cannot exclude the possibility that
any effect of TDF/FTC use was attenuated due to overall
poor adherence. Even with these limitations, our finding ofup. (N=61 for weeks 0–12 and N=49 for weeks 16–24).
Table 2
MPA levels at the end of the injection interval (week 12) by study arm.
N Mean (95% CL) % b 0.2 ng/ml % b 0.1 ng/ml % b 0.02 ng/ml
Interval 1
Placebo 35 0.49 (0.40, 1.27) 28.6 20.0 5.7
TDF/FTC 26 0.37 (0.25, 1.99) 46.2 34.6 15.4
Pooled 61 0.44 (0.39, 1.14) 36.1 26.2 9.8
Interval 2
Placebo 30 0.39 (0.31, 1.17) 30.0 23.3 6.7
TDF/FTC 19 0.28 (0.19, 1.22) 47.4 31.6 10.5
Pooled 49 0.35 (0.30, 0.84) 36.7 26.5 8.2
44 K. Nanda et al. / Contraception 94 (2016) 40–47no evidence of a significant pharmacokinetic interaction is
expected given that neither TDF nor FTC are cytochrome
p450 enzyme inducers, and thus would be unlikely to
increase MPA metabolism. Similar results were seen in a
study of COC users where co-administration of TDF resulted
in no change in ethinyl estradiol (EE) and norelgestromin
levels [18]. Unexpectedly, we found noticeably lower MPA
levels in both study groups at the end of the 12-week dosing
interval than have been reported elsewhere [8,10–13]. More
than a quarter of women had levels below the presumed
contraceptive threshold of 0.1 ng/ml, and nearly 10% had
levels below the assay detection limit.
The lowMPA trough levels seen in our study are reflected
in the relatively higher pregnancy rate among DMPA users
in Bondo (3.1 per 100 woman-years) compared with DMPA
users at the other FEM-PrEP sites (0.7 per 100 woman-years)
that used another DMPA product, Petogen manufactured by
Helm AG (Hamburg, Germany). The lowest MPA concen-
trations believed necessary to suppress ovulation ranges
from 0.1 to 0.2 ng/mL [8,9] While this threshold level is
based on very limited data and prior studies have shown that
MPA concentrations can vary quite dramatically between
individuals, most published data indicate levels at three
months remain well above 0.2 ng/mL [8,10–13]. Further-
more, while the early studies on which the threshold are
based measured MPA using radioimmunoassay (RIA) which
is known to produce higher results due to cross-reactivity
with metabolites, we found lower levels than studies that
measured MPA using a comparable mass spectrometry assay
[15,16].Table 3
AUC0–12 week by injection interval and treatment group.
N Mean (95% CL)
First interval, no previous use
Placebo 8 81.9 (67.4, 106.3)
TDF/FTC 9 76.2 (65.3, 92.5)
First interval, previous use
Placebo 27 106.4 (91.9, 127.2)
TDF/FTC 16 95.8 (77.7, 125.9)
Second interval
Placebo 29 93.7 (84.8, 105.5)
TDF/FTC 19 91.8 (77.6, 113.9)The fact that numerous women in this sub-study had
levels below 0.1 ng/ml at the end of their 12-week injection
intervals raises a number of questions, including whether it is
appropriate to assume that MPA pharmacokinetics and
pharmacodynamics are sufficiently uniform across popula-
tions. Few studies compare MPA levels across populations
and published data are conflicting. While older PK studies of
intramuscular DMPA among women in Mexico and
Thailand found more rapid disappearance of MPA and
return to ovulation among Thai women compared with
Mexican women, newer studies of subcutaneous DMPA
show no racial differences [16,19]. Furthermore, the only
available data from Africa show no difference in trough
MPA levels between Black African, Indian and White South
African women [10].
It has been postulated that inter-individual differences in
MPA metabolism may be attributable to weight or body
mass index (BMI) [20–22], but we found no significant
effect of BMI on MPA levels. Also, only one woman who
became pregnant in our analysis would be considered even
slightly overweight.
Inter-individual differences in pharmacogenetics can also
have implications for drug pharmacokinetics, efficacy, and
dosage. Recent studies designed to map pharmacogenetic
traits among African populations show considerable varia-
tion in allele frequencies known to be associated with drug
metabolism [23,24]. A comprehensive review of injectable
contraception published in 1981 suggested that population
differences in the metabolism of contraceptive steroids
including DMPA is likely [25,26]; over thirty years later theable 4
ffect of Cumulative TDF/FTC use in 4-week periods on log-transformed
UC values.
Estimate (95% CI) P-value2
umulative TDF/FTC Use1 −0.00 (−0.08, 0.07) 0.904
revious MPA use: Yes Vs No 0.11 (−0.07, 0.29) 0.219
MIN20 Vs b =20 0.07 (−0.09, 0.24) 0.365
ge in years (18–24 as reference)
30+ −0.06 (−0.25, 0.13) 0.530
25–29 −0.24 (−0.46, −0.02) 0.030
1 Cumulative TDF/FTC use in the injection window (0–3).







Last DMPA injecon    ------ First posive pregnancy test
Parcipants 10756, 11540 and 11544 assigned placebo
Fig. 3. MPA levels among DMPA users who became pregnant during the FEM-PrEP trial.
45K. Nanda et al. / Contraception 94 (2016) 40–47question of whether and how DMPA metabolism varies
across populations remains unanswered.
While we cannot rule out the possibility that the low
levels of MPA measured in this study were the result of
problems with the handling and/or provision of the DMPA at
the study site, study staff and study records indicated that the
DMPA vials were stored properly, re-suspended per
instructions, and that drug caking was not observed.
Injections were given by trained nurses with prior experience
providing DMPA. Plasma samples were kept frozen at the
recommended temperature for up to 33 months. While this is
longer than the 722 day stability data reported by PPD,
contraceptive steroids such as MPA are very stable and likely
not affected by the length of storage in this study. It is always
possible that mishandling of the samples could have
occurred either at the study site, in the shipping process orat the assaying lab. However, no evidence of such problems
was documented.
Another possible explanation for our unusual results is
that the DMPA product used at the Bondo site (Femiplan) is
not equivalent to other marketed DMPA products. Given that
FEM-PrEP ended nearly four years ago, we were unable to
test samples from the DMPA product lots used during the
study. However, we did do several quality assurance tests on
two unexpired samples (manufactured in March 2011 and
May 2013) of the same product (Femiplan, distributed by
PSI, manufactured by PT Harsen). Measurement of percent
label claim of MPA per vial and pH (data not shown)
revealed the Femiplan samples to be in compliance with
specifications. However, we noted that the proportion of
MPA particles greater than 10 µm was greater than what we
had observed with other DMPA products. Furthermore, the
46 K. Nanda et al. / Contraception 94 (2016) 40–472011 Depo-Progestin sample had a greater proportion of
larger particles than the 2013 sample. It has been theorized
that the particle size of DMPA in various formulations may
play a role in duration of action and contraceptive efficacy
[19,27]. However, in prior studies, smaller particle size was
associated with more rapid absorption. A larger DMPA
particle size might be expected to have had an opposite effect
on PK profiles. It is possible that the larger particle size may
have led to agglomeration or clumping, which could
potentially affect syringeability and prevent injection of the
full dose.
Strengths of our study include a simple design and use of
a validated, highly sensitive HPLC-MS/MS MPA assay, the
same as that used for MPA analysis in studies conducted by
Pfizer which supported US FDA approval of Depo-SubQ
Provera 104 [14], as well as for several other PK studies
[15–17]. Additionally, our findings add to the exceedingly
limited data on DMPA pharmacokinetics in Africa. Howev-
er, we could only evaluate blood levels at 4 week intervals,
limiting our ability to robustly assess PK of MPA. Given the
widespread use of DMPA and the large number of DMPA
products available worldwide, our findings of lower than
expected MPA levels among DMPA users with documented
injections highlights the need for more data confirming
effectiveness of different products in different populations.
Such data should include post-marketing surveillance data
on pregnancy rates among users of the various products, PK
data of various DMPA products in different settings, and
chemical/physical tests for product quality assurance.
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